Back to News
Market Impact: 0.35
Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease
Source: Nasdaq
Healthcare & BiotechProduct Launches
Amgen reported positive topline results from its Phase 3 OASIZ 301 trial of dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease activity. The positive late-stage clinical outcome supports the drug's development and could strengthen Amgen's inflammatory-disease pipeline, though no efficacy or safety figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
AMGN0.78
More News
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Trump Says US Team Met With Iranians at UNGA
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Qualcomm releases Android chip built for AI as memory shortage weighs on smartphone market
- Alibaba says it built the ‘most powerful AI chip in China’ as the country races to catch up with the U.S.
- Alibaba says its new Zhenwu V900 is China’s most powerful AI chip